Previous 10 | Next 10 |
Image source: The Motley Fool. Geron (NASDAQ: GERN) Q4 2021 Earnings Call Mar 10, 2022 , 4:30 p.m. ET Operator Continue reading For further details see: Geron (GERN) Q4 2021 Earnings Call Transcript
Geron Corporation (GERN) Q4 2021 Earnings Conference Call March 10, 2022 4:30 PM ET Company Participants Olivia Bloom – Chief Financial Officer John Scarlett – Chairman and Chief Executive Officer Aleksandra Rizo – Executive Vice President and Chief Medical Officer Anil K...
Geron press release (NASDAQ:GERN): Q4 GAAP EPS of -$0.10 misses by $0.02. Revenue of $1M (+1900.0% Y/Y) beats by $0.94M. Shares +0.91% AH. For further details see: Geron GAAP EPS of -$0.10 misses by $0.02, revenue of $1M beats by $0.94M
Top-Line Results from IMerge Phase 3 Trial in Lower Risk MDS Expected in Early January 2023 Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company developing a first-in-class telomerase inhibitor, imetelstat, to treat hematologic malignancies, ...
Geron (NASDAQ:GERN) is scheduled to announce Q4 earnings results on Thursday, March 10th, after market close. The consensus EPS Estimate is -$0.08 (-14.3% Y/Y) and the consensus Revenue Estimate is $0.06M (+20.0% Y/Y). The company has exceeded consensus mark in Q3. For further details see: ...
Geron Corporation (Nasdaq: GERN) today announced that it will release its fourth quarter and full year 2021 financial results after the market closes on Thursday, March 10, 2022 via press release, which will be available on the Company’s website at www.geron.com/investors . G...
100s of companies run trials in Ukraine; some of them will face delays. In the long term, Ukraine may cease to be a favored location for clinical trials. However, neither Russia nor Ukraine are drug manufacturing hubs, and market exposure is minimal. For further details see:...
Investors have been waiting over a decade for Geron to deliver on its promise. IMerge data will be out by January 2023. Despite the iffy cash position and low stock price, long-term investors will wait for another year. For further details see: Geron: Just One More Year ...
Geron Corporation (Nasdaq: GERN), a late-stage biopharmaceutical company focused on the development and commercialization of treatments for hematologic malignancies, today announced that John A. Scarlett, M.D., Geron’s Chairman and Chief Executive Officer, will present a company ...
The following slide deck was published by Geron Corporation in conjunction with their 2021 Q2 earnings call. For further details see: Geron Corporation 2021 Q2 - Results - Earnings Call Presentation
News, Short Squeeze, Breakout and More Instantly...
2024-05-03 00:30:12 ET Image source: The Motley Fool. Geron (NASDAQ: GERN) Q1 2024 Earnings Call May 02, 2024 , 8:00 a.m. ET Operator Continue reading For further details see: Geron (GERN) Q1 2024 Earnings Call Transcript
Resideo Technologies Inc. (REZI) is expected to report $0.33 for Q1 2024 Schneider National Inc. (SNDR) is expected to report $0.13 for Q1 2024 Murphy Oil Corporation (MUR) is expected to report $0.82 for Q1 2024 Astronics Corp. - Class B (ATROB) is expected to report for Q1 2024 ...
June 16, 2024 PDUFA date for imetelstat NDA for the treatment of transfusion-dependent anemia in adult patients with lower-risk MDS Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company developing investigational first-in-class telomerase inhibitor, imetelsta...